These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2435121)

  • 1. [Assessment of voiding disorders and conservative pharmacological treatment of benign prostatic hypertrophy].
    Park YC; Takada M; Sugiyama T; Matsuura T; Kaneko S; Akiyama T; Kurita T; Yachiku S
    Hinyokika Kiyo; 1986 Nov; 32(11):1576-83. PubMed ID: 2435121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia.
    Oelke M; Baard J; Wijkstra H; de la Rosette JJ; Jonas U; Höfner K
    Eur Urol; 2008 Aug; 54(2):419-26. PubMed ID: 18325657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathophysiology and differential diagnosis of benign prostatic hypertrophy.
    Blaivas JG
    Urology; 1988 Dec; 32(6 Suppl):5-11. PubMed ID: 2462303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
    J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Surgery (TUR-P) as a recommended initial treatment modality for the presented case].
    Gotoh M
    Hinyokika Kiyo; 2005 Sep; 51(9):603-8. PubMed ID: 16229373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of urodynamics in the evaluation of voiding dysfunction in men after cerebrovascular accident.
    Nitti VW; Adler H; Combs AJ
    J Urol; 1996 Jan; 155(1):263-6. PubMed ID: 7490851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Conservative treatment of benign prostatic hypertrophy: reevaluation of the effect of eviprostat by subjective symptoms and uroflowmetry].
    Matsuura T; Wakabayashi A; Kaneko S; Kurita T
    Hinyokika Kiyo; 1986 Jun; 32(6):903-6. PubMed ID: 2429533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detrusor contraction duration as a urodynamic parameter of bladder outlet obstruction for evaluating men with lower urinary tract symptoms.
    Ameda K; Steele GS; Sullivan MP; Stember D; Yalla SV
    J Urol; 1998 Aug; 160(2):482-6. PubMed ID: 9679903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelized analysis of pressure-flow studies of patients with lower urinary tract symptoms due to benign prostatic enlargement.
    Valentini FA; Zimmern PE; Besson GR; Nelson PP
    Neurourol Urodyn; 2003; 22(1):45-53. PubMed ID: 12478601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dysuria and prostatic adenoma: information provided by uroflowmetry].
    Grise P; Sibert L; Pfister C
    Prog Urol; 1999 Feb; 9(1):146-50. PubMed ID: 10212969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
    de Reijke TM; Klarskov P
    BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic effect of Robaveron tablet (KN-7) on urinary disturbance by benign prostatic hypertrophy].
    Sonoda T; Endo H; Maru A; Sasaki K; Kuroda K; Takamura T; Inada F; Rokuzyo M; Ohori T; Kubo T
    Hinyokika Kiyo; 1985 Mar; 31(3):553-62. PubMed ID: 2411118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of intermittency in men with lower urinary tract symptoms.
    Reynard J; Lim C; Abrams P
    Urology; 1996 Apr; 47(4):491-6. PubMed ID: 8638356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional and anatomical effects of hormonally induced experimental prostate growth: a urodynamic model of benign prostatic hyperplasia (BPH) in the beagle.
    Yokota T; Honda K; Tsuruya Y; Nomiya M; Yamaguchi O; Gotanda K; Constantinou CE
    Prostate; 2004 Feb; 58(2):156-63. PubMed ID: 14716740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of maximum detrusor contraction power in relation to bladder emptying in patients with lower urinary tract symptoms and benign prostatic enlargement.
    Rosier PF; de Wildt MJ; de la Rosette JJ; Debruyne FM; Wijkstra H
    J Urol; 1995 Dec; 154(6):2137-42. PubMed ID: 7500477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical study of allylestrenol (Org AL-25) on patients with prostatic hypertrophy--transrectal ultrasonography and urodynamic examination].
    Ohyama M; Tanifuji T; Haraguchi C; Fujii N; Higaki Y; Yoshida H; Imamura K
    Hinyokika Kiyo; 1986 Apr; 32(4):649-59. PubMed ID: 2426933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Gallegos PJ; Frazee LA
    Pharmacotherapy; 2008 Mar; 28(3):356-65. PubMed ID: 18294115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A urodynamic study of detrusor hyperreflexia in benign prostatic hypertrophy].
    Murayama K; Katsumi T
    Hinyokika Kiyo; 1987 Mar; 33(3):375-9. PubMed ID: 2441580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
    Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E
    Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.